ORAMED PHARMACEUTICALS INC
For the period ended Mar 31, 2025. Filed May 15, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 15, 2025
ORMP$3.97-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Comprehensive Income (loss)
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
| Three months ended March 31, | |||
|---|---|---|---|
| 2025 · 2024 | |||
| REVENUES | $2,000 | $ | - |
| COST OF REVENUE | (1,987) | - | |
| GROSS PROFIT | 13 | - | |
| RESEARCH AND DEVELOPMENT EXPENSES | (2,206) | (1,179) | |
| GENERAL AND ADMINISTRATIVE EXPENSES | (2,307) | (1,783) | |
| OPERATING LOSS | (4,500) | (2,962) | |
| INTEREST EXPENSES | - | (592) | |
| FINANCIAL INCOME (EXPENSES), NET | (2,558) | 5,088 | |
| INCOME (LOSS) BEFORE TAX EXPENSES | $(7,058) | $1,534 | |
| TAX EXPENSES | (584) | - | |
| NET INCOME (LOSS) | (7,642) | 1,534 | |
| NET INCOME (LOSS) ATTRIBUTABLE TO: | |||
| NON-CONTROLLING INTERESTS | - | (2) | |
| COMPANY’S STOCKHOLDERS | $(7,642) | $1,536 | |
| BASIC INCOME (LOSS) PER SHARE OF COMMON STOCK | $(0.19) | $0.04 | |
| DILUTED INCOME (LOSS) PER SHARE OF COMMON STOCK | $(0.19) | $0.04 | |
| WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING BASIC INCOME (LOSS) PER SHARE OF COMMON STOCK | 41,228,782 | 40,835,953 | |
| WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING DILUTED INCOME (LOSS) PER SHARE OF COMMON STOCK | 41,228,782 | 41,564,007 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.